Ceftobiprole Compared With Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Results of a Phase 3, Randomized, Double-blind Trial (TARGET).

Autor:	Overcash JS; eStudySite Clinical Research, San Diego, California, USA., Kim C; Physician Alliance Research Center, Anaheim, California, USA., Keech R; Saint Joseph's Clinical Research, Anaheim, California, USA., Gumenchuk I; Vinnytsia M. I. Pyrohov Regional Clinical Hospital, Vinnytsia, Ukraine., Ninov B; UMBAL, Pleven, Bulgaria., Gonzalez-Rojas Y; Optimus U Corp, Coral Gables, Florida, USA., Waters M; eStudySite Clinical Research, San Diego, California, USA., Simeonov S; Clinic of Endocrinology, Medical University, Plovdiv, Bulgaria., Engelhardt M; Basilea Pharmaceutica International Ltd., Basel, Switzerland., Saulay M; Basilea Pharmaceutica International Ltd., Basel, Switzerland., Ionescu D; Basilea Pharmaceutica International Ltd., Basel, Switzerland., Smart JI; Basilea Pharmaceutica International Ltd., Basel, Switzerland., Jones ME; Basilea Pharmaceutica International Ltd., Basel, Switzerland., Hamed KA; Basilea Pharmaceutica International Ltd., Basel, Switzerland.
Jazyk:	angličtina
Zdroj:	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2021 Oct 05; Vol. 73 (7), pp. e1507-e1517.
DOI:	10.1093/cid/ciaa974
Abstrakt:	Background: The development of novel broad-spectrum antibiotics, with efficacy against both gram-positive and gram-negative bacteria, has the potential to enhance treatment options for acute bacterial skin and skin structure infections (ABSSSIs). Ceftobiprole is an advanced-generation intravenous cephalosporin with broad in vitro activity against gram-positive (including methicillin-resistant Staphylococcus aureus) and gram-negative pathogens. Methods: TARGET was a randomized, double-blind, active-controlled, parallel-group, multicenter, phase 3 noninferiority study that compared ceftobiprole with vancomycin plus aztreonam. The Food and Drug Administration-defined primary efficacy endpoint was early clinical response 48-72 hours after treatment initiation in the intent-to-treat (ITT) population and the European Medicines Agency-defined primary endpoint was investigator-assessed clinical success at the test-of-cure (TOC) visit. Noninferiority was defined as the lower limit of the 95% CI for the difference in success rates (ceftobiprole minus vancomycin/aztreonam) >-10%. Safety was assessed through adverse event and laboratory data collection. Results: In total, 679 patients were randomized to ceftobiprole (n = 335) or vancomycin/aztreonam (n = 344). Early clinical success rates were 91.3% and 88.1% in the ceftobiprole and vancomycin/aztreonam groups, respectively, and noninferiority was demonstrated (adjusted difference: 3.3%; 95% CI: -1.2, 7.8). Investigator-assessed clinical success at the TOC visit was similar between the 2 groups, and noninferiority was demonstrated for both the ITT (90.1% vs 89.0%) and clinically evaluable (97.9% vs 95.2%) populations. Both treatment groups displayed similar microbiological success and safety profiles. Conclusions: TARGET demonstrated that ceftobiprole is noninferior to vancomycin/aztreonam in the treatment of ABSSSIs, in terms of early clinical response and investigator-assessed clinical success at the TOC visit. Clinical Trials Registration: NCT03137173. (© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu